Pregabalin Uses
Pregabalin is FDA-approved for five specific indications: neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, neuropathic pain associated with spinal cord injury, fibromyalgia, and as adjunctive therapy for partial-onset seizures in patients 1 month of age and older. 1
FDA-Approved Indications
The official FDA-approved uses are:
- Neuropathic pain from diabetic peripheral neuropathy - Maximum dose 300 mg/day (100 mg three times daily), starting at 150 mg/day 1
- Postherpetic neuralgia - Dose range 150-300 mg/day, with option to increase to 600 mg/day in patients tolerating but not responding to 300 mg/day 1
- Adjunctive therapy for partial-onset seizures - Approved for patients as young as 1 month old, with dosing based on age and weight (2.5-14 mg/kg/day depending on patient characteristics) 1
- Fibromyalgia - Recommended dose 300-450 mg/day, starting at 150 mg/day 1
- Neuropathic pain from spinal cord injury 1
Clinical Evidence Supporting Use
Pregabalin functions as a calcium channel α2-δ ligand, binding to voltage-gated calcium channels and inhibiting neurotransmitter release 2. This mechanism explains its efficacy across multiple neuropathic pain conditions.
For diabetic peripheral neuropathy, clinical trials demonstrated that pregabalin 100-200 mg three times daily significantly improved pain scores compared to placebo, with pain relief evident as early as Week 1 1. Importantly, the 200 mg three times daily dose showed no additional benefit over 100 mg three times daily but had more adverse effects 1.
For postherpetic neuralgia, doses of 75-150 mg twice daily (or 50-100 mg three times daily) proved effective, with the option to escalate to 600 mg/day in non-responders who tolerate the initial dose 1.
Dosing Considerations
Pregabalin has linear pharmacokinetics, making dosing more straightforward than gabapentin 2. Key dosing principles:
- Start at 150 mg/day in 2-3 divided doses for most neuropathic pain conditions
- Titrate to 300 mg/day after 1-2 weeks
- Maximum dose 600 mg/day, though higher doses show inconsistent additional benefit with increased adverse effects 2
- Requires dose reduction in renal insufficiency - adjust based on creatinine clearance 2, 1
- Taper gradually over minimum 1 week when discontinuing 1
Common Pitfalls and Cautions
Dose-dependent adverse effects are the primary limitation. Dizziness and sedation occur frequently and can be minimized by starting with lower doses and titrating cautiously 2. These effects are dose-dependent, reinforcing why doses above 300 mg/day should be reserved only for patients with ongoing pain who tolerate 300 mg/day 1.
Off-label prescribing is extensive but poorly supported by evidence 3. While pregabalin is increasingly prescribed for various pain conditions beyond its approved indications, clinicians should recognize that potential benefits are uncertain for most off-label uses 3.
Concomitant opioid use is common but concerning. Studies show that restriction policies on pregabalin paradoxically led to higher opioid usage 4, yet many patients on pregabalin are already taking opioids (49% in one registry study) 5. This combination warrants careful monitoring.
Myoclonus is a rare but serious adverse effect, occurring even in patients without renal dysfunction 6. While uncommon, clinicians should be aware of this possibility.
Pregnancy considerations: Current evidence suggests pregabalin is not associated with increased risk of major congenital malformations or neurodevelopmental outcomes after adjustment for confounders, though sample sizes in studies remain small 7.
Treatment Duration and Persistence
An adequate trial requires 4 weeks at therapeutic doses 2. However, real-world data shows poor persistence: only 34% of patients purchased just one prescription, and persistence at 1 year ranged from 21.5% for neuropathic pain to 42.1% for epilepsy 5. This suggests either inadequate efficacy, intolerable side effects, or inappropriate initial prescribing.